01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
15:07 , Sep 1, 2017 |  BC Week In Review  |  Company News

AGTC and the FFB partner to advance opthalmic research

Applied Genetics Technology Corp. (NASDAQ:AGTC) provided The Foundation Fighting Blindness Inc. (Columbia, Md.) an undisclosed grant which the foundation will use to fund its My Retina Tracker registry as well as a study to determine...
07:00 , Sep 24, 2007 |  BC Week In Review  |  Company News

BioAlliance management update

BioAlliance Pharma S.A. (Euronext:BIO), Paris, France   Business: Cancer, Infectious, Drug delivery   Hired: Christian Auclair as CSO, while remaining a director of the department of biology and director of the Biotechnology and Applied Genetics...
07:00 , May 21, 2001 |  BC Week In Review  |  Company News

Applied Genetics Inc., Elan deal

The companies formed a joint venture to develop and market Applied Genetics's Dimericine topical treatment, which contains a DNA repair enzyme that reverses UV-damaged DNA in skin. ELN will invest $4 million in Applied Genetics...
08:00 , Mar 26, 2001 |  BC Week In Review  |  Clinical News

Dimericine: Phase III

Applied Genetics published in The Lancet that in an international 30-patient, 1 year trial Dimericine reduced the annual rate of new cancers by 1.6 new cancers per year (30%, p=0.006) and the annual rate of...
07:00 , Aug 10, 1998 |  BC Week In Review  |  Company News

Applied Genetics Inc. Dermatics other research news

AGI Dermatics received two SBIR grants from the National Cancer Institute. The first is a $100,000 Phase I grant to develop a second generation version of the company's T4N5 liposomes, which are in Phase III...
08:00 , Mar 11, 1996 |  BioCentury  |  Emerging Company Profile

MitoKor: The mitochondrial connection

The diseases targeted by MitoKor - Alzheimer's and Parkinson's, non-insulin dependent diabetes mellitus(NIDDM), and schizophrenia - might appear to be unconnected. What they all share, however, is a defect in the mitochondrial DNA of related...